| Ted H Yamamoto, MD | |
|
1 Medical Center Dr, Lebanon, NH 03756-1000 | |
| (603) 650-5000 | |
| Not Available |
| Full Name | Ted H Yamamoto |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 11 Years |
| Location | 1 Medical Center Dr, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689012015 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Willamette Falls Medical Center | Oregon city, OR | Hospital |
| Providence St Vincent Medical Center | Portland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Oregon | 0648183608 | 1328 |
News Archive
"Health care overhaul legislation from President Barack Obama's congressional allies would create a federal insurance czar with sweeping new powers to oversee medical plans nationwide, an idea already drawing fierce criticism," The Associated Press reports. "State insurance commissioners are objecting, saying it would duplicate what they now do without offering any better protection for consumers. Conservatives are calling it a textbook example of a big government mentality."
Researchers at University College London have made important discoveries about the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among frontline healthcare workers that could help to inform new policies for protecting staff and patients in the future.
The group, led by the Ikerbasque professor Ugo Mayor of the UPV/EHU's Department of Biochemistry and Molecular Biology, has just published in the journal Human Molecular Genetics an explanation of the mechanisms affected by Angelman syndrome.
Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells - without affecting surrounding, healthy cells.
Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced Thrombotech Ltd., a portfolio company which Hadasit holds a 24% stake in, received an IND approval from the Food and Drug Administration enabling the initiation of a Phase IIa clinical trial in the U.S.
› Verified 2 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023488343 PECOS PAC ID: 0648183608 Enrollment ID: O20031106000652 |
News Archive
"Health care overhaul legislation from President Barack Obama's congressional allies would create a federal insurance czar with sweeping new powers to oversee medical plans nationwide, an idea already drawing fierce criticism," The Associated Press reports. "State insurance commissioners are objecting, saying it would duplicate what they now do without offering any better protection for consumers. Conservatives are calling it a textbook example of a big government mentality."
Researchers at University College London have made important discoveries about the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among frontline healthcare workers that could help to inform new policies for protecting staff and patients in the future.
The group, led by the Ikerbasque professor Ugo Mayor of the UPV/EHU's Department of Biochemistry and Molecular Biology, has just published in the journal Human Molecular Genetics an explanation of the mechanisms affected by Angelman syndrome.
Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells - without affecting surrounding, healthy cells.
Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced Thrombotech Ltd., a portfolio company which Hadasit holds a 24% stake in, received an IND approval from the Food and Drug Administration enabling the initiation of a Phase IIa clinical trial in the U.S.
› Verified 2 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003991845 PECOS PAC ID: 5395656284 Enrollment ID: O20031113000626 |
News Archive
"Health care overhaul legislation from President Barack Obama's congressional allies would create a federal insurance czar with sweeping new powers to oversee medical plans nationwide, an idea already drawing fierce criticism," The Associated Press reports. "State insurance commissioners are objecting, saying it would duplicate what they now do without offering any better protection for consumers. Conservatives are calling it a textbook example of a big government mentality."
Researchers at University College London have made important discoveries about the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among frontline healthcare workers that could help to inform new policies for protecting staff and patients in the future.
The group, led by the Ikerbasque professor Ugo Mayor of the UPV/EHU's Department of Biochemistry and Molecular Biology, has just published in the journal Human Molecular Genetics an explanation of the mechanisms affected by Angelman syndrome.
Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells - without affecting surrounding, healthy cells.
Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced Thrombotech Ltd., a portfolio company which Hadasit holds a 24% stake in, received an IND approval from the Food and Drug Administration enabling the initiation of a Phase IIa clinical trial in the U.S.
› Verified 2 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114015971 PECOS PAC ID: 9335057447 Enrollment ID: O20031117000153 |
News Archive
"Health care overhaul legislation from President Barack Obama's congressional allies would create a federal insurance czar with sweeping new powers to oversee medical plans nationwide, an idea already drawing fierce criticism," The Associated Press reports. "State insurance commissioners are objecting, saying it would duplicate what they now do without offering any better protection for consumers. Conservatives are calling it a textbook example of a big government mentality."
Researchers at University College London have made important discoveries about the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among frontline healthcare workers that could help to inform new policies for protecting staff and patients in the future.
The group, led by the Ikerbasque professor Ugo Mayor of the UPV/EHU's Department of Biochemistry and Molecular Biology, has just published in the journal Human Molecular Genetics an explanation of the mechanisms affected by Angelman syndrome.
Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells - without affecting surrounding, healthy cells.
Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced Thrombotech Ltd., a portfolio company which Hadasit holds a 24% stake in, received an IND approval from the Food and Drug Administration enabling the initiation of a Phase IIa clinical trial in the U.S.
› Verified 2 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093976243 PECOS PAC ID: 3476450560 Enrollment ID: O20031217000186 |
News Archive
"Health care overhaul legislation from President Barack Obama's congressional allies would create a federal insurance czar with sweeping new powers to oversee medical plans nationwide, an idea already drawing fierce criticism," The Associated Press reports. "State insurance commissioners are objecting, saying it would duplicate what they now do without offering any better protection for consumers. Conservatives are calling it a textbook example of a big government mentality."
Researchers at University College London have made important discoveries about the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among frontline healthcare workers that could help to inform new policies for protecting staff and patients in the future.
The group, led by the Ikerbasque professor Ugo Mayor of the UPV/EHU's Department of Biochemistry and Molecular Biology, has just published in the journal Human Molecular Genetics an explanation of the mechanisms affected by Angelman syndrome.
Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells - without affecting surrounding, healthy cells.
Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced Thrombotech Ltd., a portfolio company which Hadasit holds a 24% stake in, received an IND approval from the Food and Drug Administration enabling the initiation of a Phase IIa clinical trial in the U.S.
› Verified 2 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568547503 PECOS PAC ID: 5294623245 Enrollment ID: O20040310000315 |
News Archive
"Health care overhaul legislation from President Barack Obama's congressional allies would create a federal insurance czar with sweeping new powers to oversee medical plans nationwide, an idea already drawing fierce criticism," The Associated Press reports. "State insurance commissioners are objecting, saying it would duplicate what they now do without offering any better protection for consumers. Conservatives are calling it a textbook example of a big government mentality."
Researchers at University College London have made important discoveries about the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among frontline healthcare workers that could help to inform new policies for protecting staff and patients in the future.
The group, led by the Ikerbasque professor Ugo Mayor of the UPV/EHU's Department of Biochemistry and Molecular Biology, has just published in the journal Human Molecular Genetics an explanation of the mechanisms affected by Angelman syndrome.
Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells - without affecting surrounding, healthy cells.
Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced Thrombotech Ltd., a portfolio company which Hadasit holds a 24% stake in, received an IND approval from the Food and Drug Administration enabling the initiation of a Phase IIa clinical trial in the U.S.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ted H Yamamoto, MD 1 Medical Center Dr, Lebanon, NH 03756-1000 Ph: () - | Ted H Yamamoto, MD 1 Medical Center Dr, Lebanon, NH 03756-1000 Ph: (603) 650-5000 |
News Archive
"Health care overhaul legislation from President Barack Obama's congressional allies would create a federal insurance czar with sweeping new powers to oversee medical plans nationwide, an idea already drawing fierce criticism," The Associated Press reports. "State insurance commissioners are objecting, saying it would duplicate what they now do without offering any better protection for consumers. Conservatives are calling it a textbook example of a big government mentality."
Researchers at University College London have made important discoveries about the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among frontline healthcare workers that could help to inform new policies for protecting staff and patients in the future.
The group, led by the Ikerbasque professor Ugo Mayor of the UPV/EHU's Department of Biochemistry and Molecular Biology, has just published in the journal Human Molecular Genetics an explanation of the mechanisms affected by Angelman syndrome.
Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells - without affecting surrounding, healthy cells.
Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced Thrombotech Ltd., a portfolio company which Hadasit holds a 24% stake in, received an IND approval from the Food and Drug Administration enabling the initiation of a Phase IIa clinical trial in the U.S.
› Verified 2 days ago
Elias Loukas, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc Section Of Hospital Medicine, Lebanon, NH 03756 Phone: 603-650-8380 | |
Dr. Michael W Winter, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: One Medical Center Drive, Gastroenterology, Lebanon, NH 03756 Phone: 603-650-5261 | |
Hannah Elizabeth Foote Bensimhon, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
Victoria Forbes, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5516 | |
Zanira Fazal, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 18 Old Etna Rd, Lebanon, NH 03766 Phone: 603-650-4000 | |
Susan Si-yao Wang, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dartmouth-hitchcock Medical Ctr, Department Of Medicine, Lebanon, NH 03756 Phone: 603-650-9480 | |
Mark Edward Splaine, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Dhmc Section Of General Internal Medicine, Lebanon, NH 03756 Phone: 603-653-9500 |